Atrial fibrillation (AFib) is a kind of irregular heartbeat, or arrhythmia. A problem with the electrical signals that control your heart’s pumping action causes it to beat too fast in a pattern that ...

A cardioversion procedure can reset your heart to its normal rhythm. There are two types: Electrical cardioversion. Your doctor gives your heart an electrical shock through paddles or patches on your ...

Cardiologists at University of Utah Health use this therapy for people with heart rhythm disorders (arrhythmias), including atrial flutter and atrial fibrillation (AFib). Your heart’s electrical ...

Maze surgery, or surgical ablation, is a procedure commonly recommended to treat an irregular heartbeat (atrial fibrillation) when other methods such as medication, cardioversion therapy (electric ...

Pharmacological- and electrical-first cardioversion worked similarly well for treating acute atrial fibrillation (Afib) in the emergency department, according to the Canadian RAFF2 trial. The 204 ...

DES PLAINES, IL -- A multicenter randomized controlled clinical trial confirms that both chemical-first and electrical-first approaches are effective strategies for acute atrial fibrillation; however, ...

Patients with recent-onset atrial fibrillation commonly undergo immediate restoration of sinus rhythm by pharmacologic or electrical cardioversion. However, whether immediate restoration of sinus ...

ORLANDO, Fla. (Ivanhoe Newswire) - It is expected that within the next 20 years, 20-60 million people will get atrial fibrillation, usually just called AFib. People with AFib have a five-times ...

Background: Several clinical factors have been studied to predict atrial fibrillation (AF) recurrence after electrical cardioversion (ECV) with limited predictive value. Methods: A method able to ...

Electrical cardioversion without routine extra anticoagulation around the procedure may be feasible for people who've already received left atrial appendage (LAA) occlusion, according to a small ...

Acesion Pharma has early clinical evidence that its new approach to treating atrial fibrillation works. In a phase 2 clinical trial, recipients of the biotech’s first-in-class ion channel inhibitor ...